Ant venom immunotherapy in Australia: The unmet need

R.J. Mullins, Simon Brown

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.
    Original languageEnglish
    Pages (from-to)33-34
    JournalMedical Journal of Australia
    Volume201
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Ant venom immunotherapy in Australia: The unmet need'. Together they form a unique fingerprint.

  • Cite this